[go: up one dir, main page]

WO1998020009A1 - (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl] -2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor - Google Patents

(4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl] -2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor Download PDF

Info

Publication number
WO1998020009A1
WO1998020009A1 PCT/US1997/020036 US9720036W WO9820009A1 WO 1998020009 A1 WO1998020009 A1 WO 1998020009A1 US 9720036 W US9720036 W US 9720036W WO 9820009 A1 WO9820009 A1 WO 9820009A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
hiv
formula
reverse transcriptase
compounds
Prior art date
Application number
PCT/US1997/020036
Other languages
English (en)
French (fr)
Inventor
James David Rodgers
Patrick Yuk-Sun Lam
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EEP199900187A priority Critical patent/EE9900187A/xx
Priority to SI9720071A priority patent/SI9720071A/sl
Priority to AU51033/98A priority patent/AU722489B2/en
Priority to EA199900451A priority patent/EA001154B1/ru
Priority to EP97945596A priority patent/EP0937066A1/en
Priority to IL12972697A priority patent/IL129726A0/xx
Priority to JP52168298A priority patent/JP2001503429A/ja
Priority to BR9712755-8A priority patent/BR9712755A/pt
Priority to PL97333412A priority patent/PL333412A1/xx
Priority to NZ335919A priority patent/NZ335919A/xx
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Priority to HU9904143A priority patent/HUP9904143A3/hu
Priority to CA002270963A priority patent/CA2270963A1/en
Priority to SK595-99A priority patent/SK59599A3/sk
Publication of WO1998020009A1 publication Critical patent/WO1998020009A1/en
Priority to LVP-99-75A priority patent/LV12374B/en
Priority to NO992229A priority patent/NO992229L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • This invention relates generally to a 1- (3-aminoindazol- 5-yl) -3-butyl-cyclic urea which is useful as inhibitors of HIV protease, pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as assay standards or reagents.
  • HIV seropositive individuals are initially asymptomatic but typically develop AIDS related complex (ARC) followed by AIDS. Affected individuals exhibit severe immunosuppression which predisposes them to debilitating and ultimately fatal opportunistic infections.
  • ARC AIDS related complex
  • the disease AIDS is the end result of an HIV-1 or HIV-2 virus following its own complex life cycle.
  • the virion life cycle begins with the virion attaching itself to the host human T-4 lymphocyte immune cell through the bonding of a glycoprotein on the surface of the virion 's protective coat with the CD4 glycoprotein on the lymphocyte cell. Once attached, the virion sheds its glycoprotein coat, penetrates into the membrane of the host cell, and uncoats its RNA.
  • the virion enzyme, reverse transcriptase directs the process of transcribing the RNA into single-stranded DNA. The viral RNA is degraded and a second DNA strand is created. The now double-stranded DNA is integrated into the human cell's genes and those genes are used for cell reproduction.
  • the human cell carries out its reproductive process by using its own RNA polymerase to transcribe the integrated DNA into viral RNA.
  • the viral RNA is translated into the precursor gag-pol fusion polyprotein.
  • the polyprotein is then cleaved by the HIV protease enzyme to yield the mature viral proteins.
  • HIV protease in responsible for regulating a cascade of cleavage events that lead to the virus particle's maturing into a virus that is capable of full infectivity.
  • the typical human immune system response killing the invading virion, is taxed because a large portion of the virion' s life cycle is spent in a latent state within the immune cell.
  • viral reverse transcriptase the enzyme used in making a new virion particle, is not very specific, and causes transcription mistakes that result in continually changed glycoproteins on the surface of the viral protective coat. This lack of specificity decreases the immune system's effectiveness because antibodies specifically produced against one glycoprotein may be useless against another, hence reducing the number of antibodies available to fight the virus. The virus continues to reproduce while the immune response system continues to weaken.
  • the HIV largely holds free reign over the body's immune system, allowing opportunistic infections to set in and without the administration of antiviral agents, immunomodulators, or both, death may result .
  • antiviral drugs There are at least three critical points in the virus's life cycle which have been identified as possible targets for antiviral drugs: (1) the initial attachment of the virion to the T-4 lymphocyte or macrophage site, (2) the transcription of viral RNA to viral DNA (reverse transcriptase, RT) , and (3) the assemblage of the new virus particle during reproduction (e.g., HIV aspartic acid protease or HIV protease) .
  • retroviruses encode a protease that is responsible for the proteolytic processing of one or more polyprotein precursors such as the pol and gag gene products. See ellink, Arch . Virol . M 1 (1988). Retroviral proteases most commonly process the gag precursor into the core proteins, and also process the pol precursor into reverse transcriptase and retroviral protease.
  • the ability to inhibit a viral protease provides a method for blocking viral replication and therefore a treatment for viral diseases, such as AIDS, that may have fewer side effects, be more efficacious, and be less prone to drug resistance when compared to current treatments.
  • viral diseases such as AIDS
  • three HIV protease inhibitors Roche's saquinavir, Abbott's ritonavir, and Merck's indinavir, are currently being marketed and a number of potential protease inhibitors are in clinical trials, e.g.. Vertex's VX-478, Agouron's nelfinavir, Japan Energy's KNI-272, and Ciba-Geigy' s CGP 61755.
  • one object of the present invention is to provide novel protease inhibitors .
  • compositions with protease inhibiting activity comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
  • I or pharmaceutically acceptable salts or prodrug forms thereof are effective protease inhibitors.
  • the present invention provides a novel compound of formula I:
  • the present invention provides a novel pharmaceutical composition
  • a novel pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or prodrug form thereof.
  • the present invention provides a novel method for treating HIV infection which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or prodrug form thereof.
  • the present invention provides a novel method of treating HIV infection which comprises administering, in combination, to a host in need thereof a therapeutically effective amount of:
  • the reverse transcriptase inhibitor is a nucleoside reverse transcriptase inhibitor .
  • the nucleoside reverse transcriptase inhibitor is selected from AZT, 3TC, ddl, ddC, and d4T and the protease inhibitor is selected from saquinavir, ritonavir, indinavir, VX-478, nelfinavir, KNI- 272, CGP-61755, and U-103017.
  • the nucleoside reverse transcriptase inhibitor is selected from AZT and 3TC and the protease inhibitor is selected from saquinavir, ritonavir, and indinavir.
  • the nucleoside reverse transcriptase inhibitor is AZT.
  • the protease inhibitor is indinavir.
  • the present invention provides a pharmaceutical kit useful for the treatment of HIV infection, which comprises a therapeutically effective amount of: (a) a compound of formula I; and,
  • the present invention provides a novel method of inhibiting HIV present in a body fluid sample which comprises treating the body fluid sample with an effective amount of a compound of formula I.
  • the present invention to provides a novel a kit or container comprising a compound of formula I or II in an amount effective for use as a standard or reagent in a test or assay for determining the ability of a potential pharmaceutical to inhibit HIV protease, HIV growth, or both.
  • HIV reverse transcriptase inhibitor is intended to refer to both nucleoside and non-nucleoside inhibitors of HIV reverse transcriptase (RT) .
  • nucleoside RT inhibitors examples include, but are not limited to, AZT, ddC, ddl, d4T, and 3TC.
  • non-nucleoside RT inhibitors examples include, but are no limited to, viviradine
  • HIV protease inhibitor is intended to refer to compounds which inhibit HIV protease.
  • Examples include, but are not limited, saquinavir (Roche, Ro31-8959), ritonavir (Abbott, ABT-538) , indinavir (Merck, MK-639) , VX- 478 (Vertex/Glaxo Wellcome) , nelfinavir (Agouron, AG-1343) , KNI-272 (Japan Energy) , CGP-61755 (Ciba-Geigy) , and U-103017 (Pharmacia and Upjohn) . Additional examples include the cyclic protease inhibitors disclosed in WO93/07128, WO 94/19329, WO 94/22840, and PCT Application Number US96/03426.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic,
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th ed.. Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio.
  • Prodrugs are intended to include any covalently bonded carriers which release the active parent drug according to formula I or other formulas or compounds of the present invention in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of a compound of the present invention for example formula (I) , are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
  • Prodrugs include compounds of the present invention wherein the hydroxy or amino group is bonded to any group that, when the prodrug is administered to a mammalian subject, cleaves to form a free hydroxyl or free amino, respectively.
  • stable compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent . Only stable compounds are contempleted by the present invention .
  • Substituted is intended to indicate that one or more hydrogens on the atom indicated in the expression using “substituted” is replaced with a selection from the indicated group (s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • “Therapeutically effective amount” is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to inhibit HIV infection or treat the symptoms of HIV infection in a host.
  • the combination of compounds is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv. Enzyme Regul. 22:27-55 (1984) , occurs when the effect (in this case, inhibition of HIV replication) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at suboptimal concentrations of the compounds.
  • Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components .
  • Compound A can be prepared by known methods .
  • preparation of compound A is shown in Scheme 1 of Rossano et al (Tetr. Lett. 1995, 36 (28) , 4967, 4968), the contents of which are hereby incorporated by reference.
  • An additional method of preparation of compound A is shown in Example 6 of U.S. Patent No. 5,530,124, the contents of which are hereby incorporated by reference.
  • the compounds of formula I possess HIV protease inhibitory activity and are therefore useful as antiviral agents for the treatment of HIV infection and associated diseases.
  • the compounds of formula I possess HIV protease inhibitory activity and are effective as inhibitors of HIV growth.
  • the ability of the compounds of the present invention to inhibit viral growth or infectivity is demonstrated in standard assay of viral growth or infectivity, for example, using the assay described below.
  • the compounds of formula I of the present invention are also useful for the inhibition of HIV in an ex vivo sample containing HIV or expected to be exposed to HIV.
  • the compounds of the present invention may be used to inhibit HIV present in a body fluid sample (for example, a serum or semen sample) which contains or is suspected to contain or be exposed to HIV.
  • the compounds provided by this invention are also useful as standard or reference compounds for use in tests or assays for determining the ability of an agent to inhibit viral clone replication and/or HIV protease, for example in a pharmaceutical research program.
  • the compounds of the present invention may be used as a control or reference compound in such assays and as a quality control standard.
  • the compounds of the present invention may be provided in a commercial kit or container for use as such standard or reference compound.
  • the compounds of the present invention may also be useful as diagnostic reagents in diagnostic assays for the detection of HIV protease.
  • inhibition of the protease activity in an assay such as the assays described herein
  • a compound of the present invention would be indicative of the presence of HIV protease and HIV virus.
  • ⁇ g denotes microgram
  • mg denotes milligram
  • g denotes gram
  • ⁇ L denotes microliter
  • mL denotes milliliter
  • L denotes liter
  • nM denotes nanomolar
  • ⁇ M denotes micromolar
  • mM denotes millimolar
  • M denotes molar
  • nm denotes nanometer.
  • Sigma stands for the Sigma-Aldrich Corp. of St. Louis, MO.
  • Plasmid pDAB 72 containing both gag and pol sequences of BH10 (bp 113-1816) cloned into PTZ 19R was prepared according to Erickson-Viitanen et al . AIDS Research and Human Retroviruses 1989, 5, 577.
  • the plasmid was linearized with Bam HI prior to the generation of in vitro RNA transcripts using the Riboprobe Gemini system II kit (Promega) with T7 RNA polymerase. Synthesized RNA was purified by treatment with RNase free DNAse (Promega) , phenol-chloroform extraction, and ethanol precipitation. RNA transcripts were dissolved in water, and stored at -70°C. The concentration of RNA was determined from the A260-
  • Biotinylated capture probes were purified by HPLC after synthesis on an Applied Biosystems (Foster City, CA) DNA synthesizer by addition of biotin to the 5' terminal end of the oligonucleotide, using the biotin-phosphoramidite reagent of Cocuzza, ret. Lett. 1989, 30, 6287.
  • the gag biotinylated capture probe (5-biotin-CTAGCTCCCTGCTTGCCCATACTA 3') was complementary to nucleotides 889-912 of HXB2 and the pol biotinylated capture probe (5 '-biotin -CCCTATCATTTTTGGTTTCCAT 3' ) was complementary to nucleotides 2374-2395 of HXB2.
  • Alkaline phosphatase conjugated oligonucleotides used as reporter probes were prepared by Syngene (San Diego, CA.) .
  • the pol reporter probe (5' CTGTCTTACTTTGATAAAACCTC 3') was complementary to nucleotides 2403-2425 of HXB2.
  • the gag reporter probe (5' CCCAGTATTTGTCTACAGCCTTCT 3') was complementary to nucleotides 950-973 of HXB2. All nucleotide positions are those of the GenBank Genetic Sequence Data Bank as accessed through the Genetics Computer Group Sequence Analysis Software Package (Devereau Nucleic Acids Research 1984, 12, 387).
  • the reporter probes were prepared as 0.5 ⁇ M stocks in 2 x SSC (0.3 M NaCl, 0.03 M sodium citrate), 0.05 M Tris pH 8.8, 1 mg/mL BSA.
  • the biotinylated capture probes were prepared as 100 ⁇ M stocks in water.
  • Streptavidin coated plates were obtained from Du Pont Biotechnology Systems (Boston, MA) .
  • MT-2 and MT-4 cells were maintained in RPMI 1640 supplemented with 5% fetal calf serum (FCS) for MT-2 cells or 10% FCS for MT-4 cells, 2 mM L-glutamine and 50 ⁇ g/mL gentamycin, all from Gibco .
  • HIV-1 RF was propagated in MT-4 cells in the same medium. Virus stocks were prepared approximately 10 days after acute infection of MT-4 cells and stored as aliquots at -70°C. Infectious titers of HIV-1 (RF) stocks were 1-3 x 10 ⁇ PFU (plaque forming units) /mL as measured by plaque assay on MT-2 cells (see below) . Each aliquot of virus stock used for infection was thawed only once.
  • FCS fetal calf serum
  • cells to be infected were subcultured one day prior to infection. On the day of infection, cells were resuspended at 5 x 10 ⁇ cells/mL in RPMI 1640, 5% FCS for bulk infections or at 2 x 10 ⁇ /mL in Dulbecco's modified Eagles medium with 5% FCS for infection in microtiter plates. Virus was added and culture continued for 3 days at 37°C.
  • HIV RNA assay
  • RNA hybridization reactions were diluted three-fold with deionized water to a final guanidinium isothiocyanate concentration of 1 M and aliquots (150 ⁇ L) were transferred to streptavidin coated 5 microtiter plates wells.
  • Binding of capture probe and capture probe-RNA hybrid to the immobilized streptavidin was allowed to proceed for 2 hours at room temperature, after which the plates were washed 6 times with DuPont ELISA plate wash buffer (phosphate buffered saline (PBS), 0.05% Tween 20.)
  • DuPont ELISA plate wash buffer phosphate buffered saline (PBS), 0.05% Tween 20.
  • 35 Cells were incubated with compounds for 30 minutes at 37°C in a C ⁇ 2 incubator.
  • an appropriate dilution of HIV-1 (RF) virus stock 50 ⁇ L was added to culture wells containing cells and dilutions of the test compounds. The final volume in each well was 200 ⁇ L. Eight wells per plate were left uninfected with 50 ⁇ L of medium added in place of virus, while eight wells were infected in the absence of any antiviral compound.
  • parallel plates were cultured without virus infection.
  • IC90 values concentration of compound required to reduce the HIV RNA level by 90%
  • ddC dideoxycytidine
  • IC90 values of other antiviral compounds, both more and less potent than ddC were reproducible using several stocks of HIV-1 (RF) when this procedure was followed.
  • This concentration of virus corresponded to ⁇ 3 x 10 ⁇ PFU (measured by plaque assay on MT-2 cells) per assay well and typically produced approximately 75% of the maximum viral RNA level achievable at any virus inoculum.
  • IC90 values were determined from the percent reduction of net signal (signal from infected cell samples minus signal from uninfected cell samples) in the RNA assay relative to the net signal from infected, untreated cells on the same culture plate (average of eight wells) .
  • Valid performance of individual infection and RNA assay tests was judged according to three criteria. It was required that the virus infection should result in an RNA assay signal equal to or greater than the signal generated from 2 ng of pDAB 72 in vitro RNA transcript.
  • the IC90 for ddC, determined in each assay run, should be between 0.1 and 0.3 ⁇ g/mL.
  • the plateau level of viral RNA produced by an effective protease inhibitor should be less than 10% of the level achieved in an uninhibited infection. A compound was considered active if its IC 90 was found to be less than l ⁇ M.
  • the antiviral compounds of this invention can be administered as treatment for viral infections by any means that produces contact of the active agent with the agent ' s site of action, i.e., the viral protease, in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but preferably are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the dosage administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired.
  • a daily dosage of active ingredient can be expected to be about 0.001 to about 1000 milligrams per kilogram of body weight, with the preferred dose being about 0.1 to about 30 mg/kg.
  • compositions suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit.
  • the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
  • the active ingredient can be administered orally in solid dosage forms, such as capsules, tablets and powders, or in liquid dosage forms, such as elixirs, syrups and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.
  • Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
  • water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances.
  • Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
  • citric acid and its salts, and sodium EDTA are also used.
  • parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol .
  • Suitable pharmaceutical carriers are described in Remington 's Pharmaceutical Sciences, supra, a standard reference text in this field.
  • a large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with
  • a mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil can be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules should then be washed and dried.
  • a digestible oil such as soybean oil, cottonseed oil or olive oil
  • Tablets A large number of tablets can be prepared by conventional procedures so that the dosage unit is 100 mg of active ingredient, 0.2 mg of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch and 98.8 mg of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.
  • An aqueous suspension can be prepared for oral administration so that each 5 ml contain 25 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 mg of vanillin.
  • a parenteral composition suitable for administration by injection can be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution is sterilized by commonly used techniques .
  • Each therapeutic agent component of this invention can independently be in any dosage form, such as those described above, and can also be administered in various ways, as described above.
  • component (b) is to be understood to represent one or more agents as described previously.
  • each agent of component (b) may also be treated the same or independently.
  • Components (a) and (b) of the present invention may be formulated together, in a single dosage unit (that is, combined together in one capsule, tablet, powder, liquid, etc.) as a combination product.
  • component (a) and (b) are not formulated together in a single dosage unit, component (a) may be administered at the same time as component (b) or in any order; for example component (a) of this invention may be administered first, followed by administration of component (b) , or they may be administered in the reverse order. If component (b) contains more that one agent, e.g., one RT inhibitor and one protease inhibitor, these agents may be administered together or in any order.
  • the administration of component (a) and (b) occurs less than about one hour apart.
  • the route of administration of component (a) and (b) is oral.
  • oral agent oral inhibitor, oral compound, or the like, as used herein, denote compounds which may be orally administered.
  • component (a) and component (b) both be administered by the same route (that is, for example, both orally) or dosage form, if desired, they may each be administered by different routes (that is, for example, one component of the combination product may be administered orally, and another component may be administered intravenously) or dosage forms.
  • the dosage of the combination therapy of the invention may vary depending upon various factors such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, and the effect desired, as described above.
  • the proper dosage of components (a) and (b) of the present invention will be readily ascertainable by a medical practitioner skilled in the art, based upon the present disclosure.
  • typically a daily dosage may be about 100 milligrams to about 1.5 grams of each component. If component (b) represents more than one compound, then typically a daily dosage may be about 100 milligrams to about 1.5 grams of each agent of component (b) .
  • the dosage amount of each component may be reduced by about 70- 80% relative to the usual dosage of the component when it is administered alone as a single agent for the treatment of HIV infection.
  • the combination products of this invention may be formulated such that, although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized. In order to minimize contact, for example, where the product is orally administered, one active ingredient may be enteric coated.
  • enteric coating one of the active ingredients it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines.
  • Another embodiment of this invention where oral administration is desired provides for a combination product wherein one of the active ingredients is coated with a sustained-release material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients.
  • the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine.
  • Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low viscosity grade of hydroxypropyl methylcellulose or other appropriate materials as known in the art, in order to further separate the active components.
  • the polymer coating serves to form an additional barrier to interaction with the other component. In each formulation wherein contact is prevented between components
  • Dosage forms of the combination products of the present invention wherein one active ingredient is enteric coated can be in the form of tablets such that the enteric coated component and the other active ingredient are blended together and then compressed into a tablet or such that the enteric coated component is compressed into one tablet layer and the other active ingredient is compressed into an additional layer.
  • one or more placebo layers may be present such that the placebo layer is between the layers of active ingredients.
  • dosage forms of the present invention can be in the form of capsules wherein one active ingredient is compressed into a tablet or in the form of a plurality of microtablets, particles, granules or non-perils, which are then enteric coated. These enteric coated microtablets, particles, granules or non-perils are then placed into a capsule or compressed into a capsule along with a granulation of the other active ingredient.
  • kits useful for the treatment of HIV infection which comprise a therapeutically effective amount of a pharmaceutical composition comprising a compound of component (a) and one or more compounds of component (b) , in one or more sterile containers, are also within the ambit of the present invention. Sterilization of the container may be carried out using conventional sterilization methodology well known to those skilled in the art. Component (a) and component (b) may be in the same sterile container or in separate sterile containers.
  • kits may further include, if desired, one or more of various conventional pharmaceutical kit components, such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/US1997/020036 1996-11-08 1997-11-04 (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl] -2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor WO1998020009A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
PL97333412A PL333412A1 (en) 1996-11-08 1997-11-04 1-(3-aminoindazol-5-yl)-3-butyl cyclic urea useful as an inhibitor of hiv protease
AU51033/98A AU722489B2 (en) 1996-11-08 1997-11-04 (4r,5s,6s,7r)-hexahydro-1- {5-(3-aminoinazole)methyl} -3-butyl-5,6-dihydr oxy-4,7-bis {phaenylmethyl} -2h-1,3-diazepin-2-one, its preparation and its use as HIV protease inhibitor
EA199900451A EA001154B1 (ru) 1996-11-08 1997-11-04 (4r,5s,6s,7r)-гексагидро-1-[5-(3-аминоиндазол)метил]-3-бутил-5,6-дигидрокси-4,7-бис[фенилметил]-2н-1,3-диазепин-2-он и его применение в качестве ингибитора вич-протеазы
EP97945596A EP0937066A1 (en) 1996-11-08 1997-11-04 (4r,5s,6s,7r)-hexahydro-1- 5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis phenylmethyl] -2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor
IL12972697A IL129726A0 (en) 1996-11-08 1997-11-04 (4R,5S,6S,7R)-Hexahydro-1-(5,(3-aminoindazole) methyl)-3-butyl-5,6-dihydroxy-4,7-bis (phenylmethyl)-2H-1,3-diazepin-2-one its preparation and its use as HIV protease inhibitor
JP52168298A JP2001503429A (ja) 1996-11-08 1997-11-04 （４ｒ，５ｓ，６ｓ，７ｒ）―ヘキサヒドロ―１―［５―（３―アミノインダゾール）メチル］―３―ブチル―５，６―ジヒドロキシ―４，７―ビス［フェニルメチル］―２ｈ―１，３―ジアゼピン―２―オンおよびそのｈｉｖプロテアーゼ阻害剤としての使用
BR9712755-8A BR9712755A (pt) 1996-11-08 1997-11-04 Composto, composição farmacêutica, método para o tratamento de infecção por hiv e kit farmacêutico útil para o tratamento de infecção por hiv
EEP199900187A EE9900187A (et) 1996-11-08 1997-11-04 HIV proteaasi inhibiitorina kasulik 1-(3-aminoindasool-5-üül)-3-butüül-tsükliline uurea
SI9720071A SI9720071A (sl) 1996-11-08 1997-11-04 1-(3-aminoindazol-5-il)-3-butil-ciklična sečnina, uporabna kot inhibitor proteaze HIV
NZ335919A NZ335919A (en) 1996-11-08 1997-11-04 (4r,5s,6s,7r)-hexahydro-1-[5-(3-aminoinazole)methyl]-3-butyl-5 ,6-dihydroxy-4,7-bis[phaenylmethyl]-2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor
HU9904143A HUP9904143A3 (en) 1996-11-08 1997-11-04 (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis [phenylmethyl] -2h-1,3-diazepin-2-one,its preparation and its use as hiv protease inhibitor
CA002270963A CA2270963A1 (en) 1996-11-08 1997-11-04 (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl] -2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor
SK595-99A SK59599A3 (en) 1996-11-08 1997-11-04 (4r,5s,6s,7r)-hexahydro-1-[5-(3-aminoinazole)methyl]-3-butyl- -5,6-dihydroxy-4,7-bis [phaenylmethyl]-2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor
LVP-99-75A LV12374B (en) 1996-11-08 1999-04-29 (4R, 5S, 6S, 7R) -HEKSAHIDRO-1- [5- (3-AMINOINDAZOL) METIL] -3-BUTYL-5,6-DIOXY-4,7-BIS [FENILMETIL] -2H-1,3- DIAZEPIN-2-ONS, OBTAINING THIS COMPOUND AND HOW TO USE HUMAN PROTEAS INHIBITOR
NO992229A NO992229L (no) 1996-11-08 1999-05-07 (4R,5S,6S,7R)-heksahydro-1-[5-(3-aminoinazol)metyl]-3-butyl-5,6-dihydroksy-4,7-bis[fenylmetyl]-2H-1,3-diazepin-2-on, dens fremstilling og dens anvendelse som HIV-proteaseinhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2974696P 1996-11-08 1996-11-08
US74710396A 1996-11-08 1996-11-08
US60/029,746 1996-11-08
US08/747,103 1996-11-08

Publications (1)

Publication Number Publication Date
WO1998020009A1 true WO1998020009A1 (en) 1998-05-14

Family

ID=26705295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/020036 WO1998020009A1 (en) 1996-11-08 1997-11-04 (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl] -2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor

Country Status (19)

Country Link
EP (1) EP0937066A1 (xx)
JP (1) JP2001503429A (xx)
KR (1) KR20000053123A (xx)
CN (1) CN1235601A (xx)
AU (1) AU722489B2 (xx)
BR (1) BR9712755A (xx)
CA (1) CA2270963A1 (xx)
CZ (1) CZ157499A3 (xx)
EA (1) EA001154B1 (xx)
EE (1) EE9900187A (xx)
HU (1) HUP9904143A3 (xx)
IL (1) IL129726A0 (xx)
LV (1) LV12374B (xx)
NO (1) NO992229L (xx)
NZ (1) NZ335919A (xx)
PL (1) PL333412A1 (xx)
SI (1) SI9720071A (xx)
SK (1) SK59599A3 (xx)
WO (1) WO1998020009A1 (xx)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043969A1 (en) * 1997-03-31 1998-10-08 Dupont Pharmaceuticals Company Indazoles of cyclic ureas useful as hiv protease inhibitors
EP1640368A2 (fr) 2000-06-13 2006-03-29 The Centre National de la Recherche Scientifique Composés urées cycliques et leur procédé de préparation
JP2010280724A (ja) * 1998-06-24 2010-12-16 Emory Univ Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007128A1 (en) * 1991-10-11 1993-04-15 The Du Pont Merck Pharmaceutical Company Cyclic ureas and analogues useful as retroviral protease inhibitiors
WO1994019329A1 (en) * 1993-02-26 1994-09-01 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007128A1 (en) * 1991-10-11 1993-04-15 The Du Pont Merck Pharmaceutical Company Cyclic ureas and analogues useful as retroviral protease inhibitiors
WO1994019329A1 (en) * 1993-02-26 1994-09-01 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAM P.Y.S. ET AL.: "Cyclic HIV protease inhibitors: Synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 18, 30 August 1996 (1996-08-30), pages 3514 - 3525, XP002057423 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043969A1 (en) * 1997-03-31 1998-10-08 Dupont Pharmaceuticals Company Indazoles of cyclic ureas useful as hiv protease inhibitors
JP2010280724A (ja) * 1998-06-24 2010-12-16 Emory Univ Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用
EP1640368A2 (fr) 2000-06-13 2006-03-29 The Centre National de la Recherche Scientifique Composés urées cycliques et leur procédé de préparation
EP1640368A3 (fr) * 2000-06-13 2007-03-28 The Centre National de la Recherche Scientifique Composés urées cycliques et leur procédé de préparation

Also Published As

Publication number Publication date
PL333412A1 (en) 1999-12-06
KR20000053123A (ko) 2000-08-25
EA001154B1 (ru) 2000-10-30
IL129726A0 (en) 2000-02-29
SI9720071A (sl) 1999-12-31
CN1235601A (zh) 1999-11-17
EP0937066A1 (en) 1999-08-25
BR9712755A (pt) 1999-10-19
LV12374A (lv) 1999-11-20
CA2270963A1 (en) 1998-05-14
EE9900187A (et) 1999-12-15
JP2001503429A (ja) 2001-03-13
NO992229L (no) 1999-06-07
HUP9904143A2 (hu) 2000-06-28
AU722489B2 (en) 2000-08-03
AU5103398A (en) 1998-05-29
NO992229D0 (no) 1999-05-07
HUP9904143A3 (en) 2002-11-28
NZ335919A (en) 2000-09-29
CZ157499A3 (cs) 1999-11-17
SK59599A3 (en) 1999-12-10
EA199900451A1 (ru) 1999-12-29
LV12374B (en) 2000-04-20

Similar Documents

Publication Publication Date Title
US6204262B1 (en) 1,3-Benzodiazepin-2-ones and 1,3-Benzoxazepin-2-ones useful as HIV reverse transcriptase inhibitors
US5932570A (en) 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
US6218386B1 (en) A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
US6391919B1 (en) Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
AU722489B2 (en) (4r,5s,6s,7r)-hexahydro-1- {5-(3-aminoinazole)methyl} -3-butyl-5,6-dihydr oxy-4,7-bis {phaenylmethyl} -2h-1,3-diazepin-2-one, its preparation and its use as HIV protease inhibitor
EP0937067B1 (en) 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors
US6313110B1 (en) Substituted 2H-1,3-diazapin-2-one useful as an HIV protease inhibitor
AU2725700A (en) Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors
US6946469B2 (en) Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors
US7015214B2 (en) Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazepine as HIV reverse transcriptase inhibitors
US20040063734A1 (en) 4,4-Disubstituted-3,4-dihydro-2 (1H)-quinazoliniones useful as HIV reverse transcriptase inhibitors
US6562848B1 (en) Bis-amino acid sulfonamides as HIV protease inhibitors
MXPA99004286A (en) 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors
MXPA99004294A (en) (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl]-3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl]-2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor
HRP970586A2 (en) 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors
HRP970595A2 (en) 1-(3-aminoindazol-5-yl)-3-butyl-cyclic urea useful as a hiv proteaze inhibitor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97199418.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU AZ BA BR BY CA CN CU CZ EE HU IL JP KG KR KZ LC LT LV MD MX NO NZ PL RO RU SG SI SK TJ TM UA VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997945596

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 99-00450

Country of ref document: RO

ENP Entry into the national phase

Ref document number: 1999 990075

Country of ref document: LV

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999990075

Country of ref document: LV

ENP Entry into the national phase

Ref document number: 2270963

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV1999-1574

Country of ref document: CZ

Ref document number: 99045

Country of ref document: LT

Ref document number: 59599

Country of ref document: SK

Ref document number: 99-045

Country of ref document: LT

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/004294

Country of ref document: MX

Ref document number: 1019997004049

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1998 521682

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 51033/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 335919

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 199900451

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1199900457

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1997945596

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 99-045

Country of ref document: LT

WWP Wipo information: published in national office

Ref document number: PV1999-1574

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 99-045

Country of ref document: LT

WWP Wipo information: published in national office

Ref document number: 1019997004049

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 51033/98

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1997945596

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 99-045

Country of ref document: LT

WWW Wipo information: withdrawn in national office

Ref document number: 1997945596

Country of ref document: EP

Ref document number: 1019997004049

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1999-1574

Country of ref document: CZ